Tobin Schilke - 03 Mar 2026 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Reporting relationship: Chief Financial Officer
Issuer ticker: CRNX
Reported as of: 03 Mar 2026
Net transaction value: -$266,305
SEC form: 4
Accepted by SEC: 04 Mar 2026, 17:43:52 UTC
Prior SEC filing: 25 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Tobin Schilke

Key filing fact

Tobin Schilke filed Form 4 for Crinetics Pharmaceuticals, Inc. (CRNX) on 04 Mar 2026.

Key facts

This page summarizes Tobin Schilke's Form 4 filing for Crinetics Pharmaceuticals, Inc. (CRNX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 04 Mar 2026, 17:43.

Change

Previous filing in this sequence was filed on 25 Feb 2026.
Current net transaction value: -$266,305.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001678984 Primary reporting owner

Schilke Tobin

Relationship: Chief Financial Officer
Address: C/O CRINETICS PHARMACEUTICALS, INC., 6055 LUSK BOULEVARD, SAN DIEGO
Signature: /s/ Tobin Schilke
Signature date: 04 Mar 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRNX transaction

Common Stock

Sale

Transaction value: $266,305
Shares: -6,713
Change %: -7.9%
Price: $39.67
Shares after: 78,121
Date: 03 Mar 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Represents the number of shares of common stock sold by the Issuer to cover the Reporting Person's tax withholding obligation upon the vesting of Restricted Stock Units granted on March 10, 2025. The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person.

Footnote F2

The common stock was sold in open market transactions on the transaction date, with a volume weighted average sales price of $39.67 per share. The range of sales prices on the transaction date was $39.67 to $39.74 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.